Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review.
Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review.
复制标题
DOI：
10.1186/s12935-018-0624-x
复制
发表时间：
2018
影响因子：
5.8
通讯作者：
Shirian S
中科院分区：
文献类型：
--
作者：
Hosseinzadeh F;Verdi J;Ai J;Hajighasemlou S;Seyhoun I;Parvizpour F;Hosseinzadeh F;Iranikhah A;Shirian S
肝细胞癌（HCC）的高患病率和这种疾病的典型预后差，导致晚期诊断，而潜在的治愈治疗效果最差；因此，开发一种有效而系统的治疗方法是迫切需要的。本文综述了目前肝癌患者的几种治疗方法及其优缺点。此外，最近各种关于“两种有效药物，索拉非尼或自然杀伤（NK）细胞”对HCC细胞的性能的临床前和临床研究进行了调查。此外，本综述的重点是化疗-免疫治疗方法，索拉非尼和NK细胞之间的相关性以及它们在更好地抑制HCC方面相互作用的影响。结论索拉非尼和NK细胞联合治疗可能改善HCC患者的应用治疗方法的预后。最后，我们还得出结论，索拉非尼和NK细胞之间的相互作用是剂量和时间依赖的，因此，仔细的剂量和时间优化是开发联合免疫细胞疗法的必要条件。
High prevalence of hepatocellular carcinoma (HCC) and typically poor prognosis of this disease that lead to late stage diagnosis when potentially curative therapies are least effective; therefore, development of an effective and systematic treatment is an urgent requirement. In this review, several current treatments for HCC patients and their advantages or disadvantages were summarized. Moreover, various recent preclinical and clinical studies about the performances of “two efficient agents, sorafenib or natural killer (NK) cells”, against HCC cells were investigated. In addition, the focus this review was on the chemo-immunotherapy approach, correlation between sorafenib and NK cells and their effects on the performance of each other for better suppression of HCC. It was concluded that combinational therapy with sorafenib and NK cells might improve the outcome of applied therapeutic approaches for HCC patients. Finally, it was also concluded that interaction between sorafenib and NK cells is dose and time dependent, therefore, a careful dose and time optimizing is necessary for development of a combinational immune-cell therapy.
登录
查看更多内容
影响因子：
2.9
作者：
Davila JA;Duan Z;McGlynn KA;El-Serag HB
通讯作者：
El-Serag HB
影响因子：
8.7
作者：
Golden-Mason L;Rosen HR
通讯作者：
Rosen HR
影响因子：
4.6
作者：
Gomez-Martin, Carlos;Bustamante, Javier;Sangro, Bruno
通讯作者：
Sangro, Bruno
影响因子：
56.9
作者：
Bauer, S;Groh, V;Spies, T
通讯作者：
Spies, T
索拉非尼对亚太地区晚期肝细胞癌患者的疗效和安全性：一项 III 期随机、双盲、安慰剂对照试验
影响因子：
51.1
作者：
Cheng, Ann-Lii;Kang, Yoon-Koo;Guan, Zhongzhen
通讯作者：
Guan, Zhongzhen